TrialJectory and OncoBay Clinical Partner to Connect All Cancer Patients to Advanced Treatment Options
TrialJectory and OncoBay Clinical Partner to Connect All Cancer Patients to Advanced Treatment Options
Partnership’s Mission Aims to Eradicate Socioeconomic, Racial and Geographic Barriers to Effective Cancer Care
New York, N.Y., and Tampa, Fla. – September30,2020– TrialJectory, an AI-powered technology platform that empowers cancer patients to find advanced new treatment options that fit their precise profile, and OncoBay Clinical, Inc., a full-service boutique contract research organization (CRO) specializing in the simplification of complex oncology programs, today announced a new partnership to more effectively connect cancer patients with advanced treatment options through improved access to clinical trials. With this collaboration, OncoBay will leverage TrialJectory’s AI-based advanced treatment matching solution to supercharge its clinical trial recruitment efforts and expedite enrollment of the right cancer patients in the right studies. In addition, TrialJectory’s platform will be employed across OncoBay’s network of community-based sites, significantly increasing patient reach.
“OncoBay’s foundation is built on our vision to transform cancer research through innovation, collaboration and partnership to positively impact cancer patients’ lives,” said Krystyna Kowalczyk, President and CEO of OncoBay. “Our unique partnership with TrialJectory is tapping into the power of AI and technology to do just that. Together, we are eliminating patient barriers to access for the most advanced and potentially lifesaving treatments that are out there today.”
Cancer patients who do not live by major research hospitals in the U.S. are at an extreme disadvantage. Since accessing patients through their physician communities is fundamental, OncoBay has established core site relationships through its specialized oncology networks, including community-based sites, which have been vetted specifically for their ability to activate quickly, identify large numbers of patients and integrate successfully within the OncoBay Clinical technology ecosystem. Working with these sites allows for unparalleled patient access.
TrialJectory uses AI to curate, structure and personalize massive quantities of data produced by cancer research every day and makes the experience of being matched to the right trial fast and patient friendly. Once patients have been matched to an advanced treatment, they are connected with trial specialists who support the patients’ needs from beginning to end as they apply, enroll, and participate in the study.
“Accessing clinical trials should be easy for all patients, no matter where they are located, as they often provide better alternatives compared with the standard of care,” added Tzvia Bader, Co-Founder and CEO of TrialJectory. “On top of fighting for their lives every day, cancer patients are up against countless barriers to entry when it comes to finding advanced treatment options that are a perfect fit for them. To truly enact meaningful change in the cancer space, we must bring technology directly into the hands of cancer patients to help them find the best treatment options. OncoBay and TrialJectory are tackling these issues head-on in hopes of bringing advanced new treatments to the forefront of cancer care. Together, TrialJectory and OncoBay are connecting patients to hope.”
About TrialJectory
TrialJectory is a patient-first digital health company with a mission to democratize access to advanced cancer treatment. TrialJectory uses artificial intelligence (AI) to empower patients to own their cancer journey and analyzes its global patient community’s real-world data to empower cancer patients to make the most informed decisions about their care. For more information, please visit www.trialjectory.com.
About OncoBay Clinical
OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit Oncobay.com and follow us on Facebook, Twitter and LinkedIn.
###
Media Contacts for TrialJectory
Caitlin Kasunich / Shana Marino
KCSA Strategic Communications
ckasunich@kcsa.com / smarino@kcsa.com
Media Contacts for OncoBay Clinical
Deborah Turunjian
dturunjian@oncobay.com
